Purpose: This review systematically compared, in a head-to-head manner, the diagnostic and prognostic performance of [F]FDG and [F]FES PET/CT in breast cancer (BC) patients.
Methods: A systematic literature search was conducted in PubMed, Scopus, and Web of Science databases up to January 2025, without temporal limitations or restrictions on the number of patients in the included studies, to identify relevant articles comparing the diagnostic value of [F]FDG and [F]FES PET in BC patients. Selected imaging studies were analyzed using a modified version of the Critical Appraisal Skills Programme checklist dedicated to systematic reviews.
Results: A total of 20 papers were evaluated. Based on the CASP analysis, the quality of the study was variable. Totally, 806 patients affected by BC underwent both [F]FDG and [F]FES PET. Different setting of disease were considered, such as staging/diagnostic and prognostic value. In the initial staging of disease, [F]FES PET/CT seemed to be more accurate than [F]FDG. In the prognostic field, [F]FES expression was a positive factor for the better prognosis, in particular when the amount of [F]FDG uptake was low. [F]FES seemed to be promising as a molecular agent in patients affected by invasive lobular BC.
Conclusion: These findings underscore the potential of [F]FES as a complementary imaging biomarker to [F]FDG, advocating for further studies to standardize PET metrics and refine their combined clinical utility.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-025-07186-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Head-to-Head comparison of [F]FES and [F]FDG PET/CT in breast cancer patients: has a new era come?
Eur J Nucl Med Mol Imaging
March 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Purpose: This review systematically compared, in a head-to-head manner, the diagnostic and prognostic performance of [F]FDG and [F]FES PET/CT in breast cancer (BC) patients.
Methods: A systematic literature search was conducted in PubMed, Scopus, and Web of Science databases up to January 2025, without temporal limitations or restrictions on the number of patients in the included studies, to identify relevant articles comparing the diagnostic value of [F]FDG and [F]FES PET in BC patients. Selected imaging studies were analyzed using a modified version of the Critical Appraisal Skills Programme checklist dedicated to systematic reviews.
The Diagnostic Accuracy of F-FDG PET and F-FES PET for Staging Grade 1-2 Estrogen Receptor-Positive Breast Cancer.
Radiology
March 2025
From the Departments of Medical Oncology (J.J.K., R.I., E.C.B., I.R.K., C.W.M.v.d.H.v.O.), Surgery (G.M.P.D., S.v.d.V.), Radiology and Nuclear Medicine (L.J.S., K.D., G.J.C.Z., A.D.W., R.B., D.E.O.L.), and Pathology (E.B.), Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, the Netherlands (J.J.K., R.I., I.R.K., G.J.C.Z., R.B., D.E.O.L., C.W.M.v.d.H.v.O.); Departments of Medical Oncology (L.H.M.) and Nuclear Medicine (J.J.M.T.), Reinier de Graaf Gasthuis, Delft, the Netherlands; Department of Medical Oncology, Ziekenhuis Amstelland, Amstelveen, the Netherlands (A.A.v.Z., P.P.); Department of Surgery, Flevoziekenhuis, Almere, the Netherlands (G.M.P.D.); Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands (L.J.S.); Department of Medical Oncology, Zaans Medisch Centrum, Zaandam, the Netherlands (S.D.B.); and Department of Medical Oncology, Dijklander Ziekenhuis, Hoorn, the Netherlands (N.S.).
Background According to current guidelines, staging of patients with locally advanced breast cancer and local-regional recurrent breast cancer is preferably performed with PET using 2-fluorine 18-fluoro-2-deoxy-d-glucose (F-FDG). However, F-FDG PET might underperform in low-grade estrogen receptor (ER)-positive breast cancer. Alternatively, 16α-F-fluoro-17β-estradiol (F-FES) has emerged as a powerful tracer for in vivo visualization of ER-positive lesions.
View Article and Find Full Text PDF[F]F-FES PET for diagnosis, staging, and endocrine therapy prediction in ER-positive breast cancer: a systematic review and meta-analysis.
EJNMMI Res
February 2025
Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Background: This meta-analysis evaluates the diagnostic and staging accuracy of [F]F-FES PET/CT, its ability to detect estrogen receptor (ER) positivity, and its effectiveness in predicting response to endocrine therapy in ER-positive (ER+) breast cancer. A systematic search of PubMed, Embase (OVID), and Web of Science databases was conducted for studies published between 2013 and June 2024. Studies involving ER + breast cancer patients who underwent [F]F-FES PET/CT were included.
View Article and Find Full Text PDFIntrapatient 16α-[F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
J Nucl Med
February 2025
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Intrapatient heterogeneity of estrogen receptor (ER) expression on 16α-[F]fluoro-17β-estradiol ([F]FES) PET is related to outcome in patients with ER-positive metastatic breast cancer (MBC), but a validated and practical method to support clinical decision-making is lacking. Therefore, the [F]FES PET heterogeneity score (i.e.
View Article and Find Full Text PDFUtility of F-fluoroestradiol over F-fluorodeoxyglucose positron emission tomography/computed tomography in the initial diagnosis of over 90 metastatic lesions in a patient with metastatic estrogen receptor-positive breast cancer.
Proc (Bayl Univ Med Cent)
July 2024
Department of Surgery, Baylor Scott & White Medical Center-Waxahachie, Waxahachie, Texas, USA.
Approximately 6% of women with newly diagnosed breast cancer will present with metastatic disease. Proper staging workup and diagnosis of metastatic lesions is crucial prior to surgical treatment.F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is often included in the staging workup of locally advanced breast cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!